Drug-related issues and pharmaceutical interventions in tuberculosis patients
DOI:
https://doi.org/10.21722/rbps.v22i1.19077Keywords:
Tuberculosis, Drug therapy, Pharmaceutical careAbstract
Introduction:
Tuberculosis (TB) is an infectious disease whose long-term pharmacological therapy contributes to treatment abandonment and to negative health outcomes. Pharmaceutical care has successfully improved treatment adherence and reduced the number of drug-related issues (DRI). Objective: Identifying DRI and tracing the profile of pharmaceutical interventions (PI) in tuberculosis patients treated in a hospital institution. Methods: Cross-sectional, prospective, interventional and quantitative study carried out from February to October 2017. Recommendations by the Brazilian Ministry of Health for the implementation of Pharmaceutical Clinical Services were used as method to identify and classify DRI and PI. Drug prescriptions and patients’ medical records were also used as data collection source. Results: Thirty-three individuals at mean age of 40.41 (± 13) years participated in the study. In total, 278 DRI were identified, the most frequent ones lied on issues involving drug selection and prescription (n = 215; 77.3%), as well as adverse reaction to drugs (n = 13, 4.7%). The total number of 296 PIs were performed, mainly information and counseling (n = 99; 33.5%) and drug interaction management (n = 80; 27%). Conclusion: DRI cases were common in the current study, as well as the need of PI. This outcome suggests that pharmaceutical clinical services have the potential to help multiprofessional health teams to identify and manage drug-related issues, as well as to help achieving better health outcomes in tuberculosis patients.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Revista Brasileira de Pesquisa em Saúde/Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Revista Brasileira de Pesquisa em Saúde (RBPS) adopts the CC BY 4.0 license, which means that authors retain the copyright of the works they submit to the journal. Authors are responsible for declaring that their contribution is an original manuscript, that it has not been previously published, and that it is not under simultaneous review by another scientific journal. Upon submitting the manuscript, authors grant RBPS the exclusive right of first publication, subject to peer review.
Authors are permitted to enter into additional contracts for the non-exclusive distribution of the version published by RBPS (for example, in institutional repositories or as a book chapter), provided that due acknowledgment of authorship and of initial publication by RBPS is given. Authors are also encouraged to make their work available online (for example, in institutional repositories or on their personal pages) after its initial publication in the journal, with due acknowledgment of authorship and of the original publication by RBPS.
Accordingly, under the CC BY 4.0 license, readers have the right to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially;
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
